MA29683B1 - COMBINATION FOR TREATING A BENIGN HYPERPLASIE OF THE PROSTATE - Google Patents
COMBINATION FOR TREATING A BENIGN HYPERPLASIE OF THE PROSTATEInfo
- Publication number
- MA29683B1 MA29683B1 MA30335A MA30335A MA29683B1 MA 29683 B1 MA29683 B1 MA 29683B1 MA 30335 A MA30335 A MA 30335A MA 30335 A MA30335 A MA 30335A MA 29683 B1 MA29683 B1 MA 29683B1
- Authority
- MA
- Morocco
- Prior art keywords
- hyperplasie
- benign
- prostate
- treating
- combination
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
- A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5084—Mixtures of one or more drugs in different galenical forms, at least one of which being granules, microcapsules or (coated) microparticles according to A61K9/16 or A61K9/50, e.g. for obtaining a specific release pattern or for combining different drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/08—Drugs for disorders of the urinary system of the prostate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Urology & Nephrology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
Combinaison pour traiter une hyperplasie bénigne de la prostate Cette invention se rapporte à un nouveau procédé pour le traitement des symptômes associés à l'hyperplasie bénigne de la prostate couramment employé pour traiter médicalement l'hyperplasie bénigne de la prostate. Ceci nécessite l'utilisation concomitante : (1) d'un antagoniste des récepteurs (alpha)1-adrénergiques dans une formulation à libération contrôlée ou d'un inhibiteur de la 5-(alpha) réductase et (2) d'un inhibiteur de la PDE 5 spécifique de la GMPc dans une formulation à libération contrôlée ou d'un inhibiteur de la PDE 5 spécifique de la GMPc avec une longue demi-vie.This invention relates to a novel method for the treatment of symptoms associated with benign prostatic hyperplasia commonly used to medically treat benign prostatic hyperplasia. This requires the concomitant use of: (1) an (alpha) 1-adrenergic receptor antagonist in a controlled release formulation or a 5- (alpha) reductase inhibitor and (2) an inhibitor of cGMP-specific PDE in a controlled release formulation or cGMP-specific PDE inhibitor with a long half-life.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102005016981A DE102005016981A1 (en) | 2005-04-13 | 2005-04-13 | Combination therapy for benign prostatic hyperplasia |
Publications (1)
Publication Number | Publication Date |
---|---|
MA29683B1 true MA29683B1 (en) | 2008-08-01 |
Family
ID=36608700
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MA30335A MA29683B1 (en) | 2005-04-13 | 2007-10-29 | COMBINATION FOR TREATING A BENIGN HYPERPLASIE OF THE PROSTATE |
Country Status (22)
Country | Link |
---|---|
EP (1) | EP1888075A1 (en) |
JP (1) | JP2008535877A (en) |
KR (1) | KR20080007252A (en) |
CN (1) | CN101193638A (en) |
AR (1) | AR053575A1 (en) |
AU (1) | AU2006233567A1 (en) |
BR (1) | BRPI0610634A2 (en) |
CA (1) | CA2605224A1 (en) |
CR (1) | CR9427A (en) |
DE (1) | DE102005016981A1 (en) |
DO (1) | DOP2006000074A (en) |
GT (1) | GT200600145A (en) |
IL (1) | IL186604A0 (en) |
MA (1) | MA29683B1 (en) |
MX (1) | MX2007012567A (en) |
PE (1) | PE20061338A1 (en) |
RU (1) | RU2007141518A (en) |
SV (1) | SV2008002477A (en) |
TN (1) | TNSN07385A1 (en) |
TW (1) | TW200716122A (en) |
UY (1) | UY29473A1 (en) |
WO (1) | WO2006108519A1 (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6143746A (en) * | 1994-01-21 | 2000-11-07 | Icos Corporation | Tetracyclic cyclic GMP-specific phosphodiesterase inhibitors, process of preparation and use |
US20070093493A1 (en) * | 2005-10-12 | 2007-04-26 | Lilly Icos Llc | Treatment of benign prostatic hypertrophy and lower urinary tract symptoms |
JP2009520806A (en) * | 2005-12-21 | 2009-05-28 | ファイザー・プロダクツ・インク | Pharmaceutical combination of PDE-5 inhibitor and 5-α reductase inhibitor |
CN101500572B (en) * | 2006-07-07 | 2013-08-21 | 特瓦制药工业有限公司 | Solid compositions comprising tadalafil and at least one carrier |
DE102007028869A1 (en) | 2007-06-22 | 2008-12-24 | Ratiopharm Gmbh | A process for the preparation of a medicament containing tadalafil |
EP2222301B1 (en) | 2007-12-13 | 2014-10-08 | Vanda Pharmaceuticals Inc. | Method and composition for treating an alpha adrenoceptor-mediated condition |
WO2009076664A1 (en) | 2007-12-13 | 2009-06-18 | Vanda Pharmaceuticals Inc. | Method and composition for treating a serotonin receptor-mediated condition |
US8885621B2 (en) | 2010-04-26 | 2014-11-11 | Intel Corporation | Method, apparatus and system for switching traffic streams among multiple bands |
WO2013123965A1 (en) * | 2012-02-20 | 2013-08-29 | Synthon Bv | A fixed dose pharmaceutical formulation |
CN102727456B (en) * | 2012-07-03 | 2016-06-22 | 北京科信必成医药科技发展有限公司 | Drug port cavity disintegrating tablet and preparation method thereof |
CN105338970B (en) * | 2013-06-28 | 2019-07-09 | 韩美药品株式会社 | Medicament capsule compound formulation comprising Tadalafei and Tamsulosin |
MX2016001030A (en) | 2013-07-23 | 2016-10-07 | Allergan Inc | Methods and compositions comprising desmopressin in combination with a beta-3 adrenergic receptor agonist. |
KR101663238B1 (en) * | 2013-11-15 | 2016-10-14 | 한미약품 주식회사 | Complex solid formulation comprising tadalafil and amlodipine |
WO2016003181A1 (en) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | Composite preparation comprising active ingredient-containing film coating layer |
WO2016003180A1 (en) * | 2014-06-30 | 2016-01-07 | 한미약품 주식회사 | Composite preparation comprising 5-α-reductase inhibitor-containing film coating layer, and method for producing the composite preparation |
ES2781110T3 (en) * | 2014-06-30 | 2020-08-28 | Hanmi Pharm Ind Co Ltd | Composite material preparation comprising a film coating layer, containing a 5-alpha-reductase inhibitor, and method for the production of the composite material preparation |
ES2923438T3 (en) * | 2014-11-20 | 2022-09-27 | Serenity Pharmaceuticals Llc | Compositions comprising low doses of desmopressin in combination with an alpha-adrenergic receptor antagonist |
KR102391495B1 (en) * | 2016-03-31 | 2022-04-28 | 한미약품 주식회사 | Capsule composite formulation containing tadalafil and tamsulosin with improved stability and dissolution |
KR101835506B1 (en) * | 2016-10-25 | 2018-03-07 | 주식회사 에스텍파마 | Rapid-acting mixture of tablet containing dutasteride and tadalafil |
CN108066347B (en) * | 2016-11-16 | 2021-02-02 | 深圳万和制药有限公司 | Orally disintegrating tablet pharmaceutical composition comprising tamsulosin and dutasteride |
KR101879133B1 (en) * | 2017-07-11 | 2018-07-17 | (주)동구바이오제약 | Agents for preventing or treating urinary disease and preparing the same |
TR201715231A2 (en) * | 2017-10-09 | 2019-04-22 | Montero Gida Sanayi Ve Ticaret Anonim Sirketi | The pharmaceutical combination comprising dapoxetine and phosphodiesterase type-5 |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20050042177A1 (en) * | 2003-07-23 | 2005-02-24 | Elan Pharma International Ltd. | Novel compositions of sildenafil free base |
-
2005
- 2005-04-13 DE DE102005016981A patent/DE102005016981A1/en not_active Withdrawn
-
2006
- 2006-03-29 DO DO2006000074A patent/DOP2006000074A/en unknown
- 2006-03-31 CA CA002605224A patent/CA2605224A1/en not_active Abandoned
- 2006-03-31 MX MX2007012567A patent/MX2007012567A/en not_active Application Discontinuation
- 2006-03-31 WO PCT/EP2006/002941 patent/WO2006108519A1/en active Application Filing
- 2006-03-31 JP JP2008505765A patent/JP2008535877A/en active Pending
- 2006-03-31 RU RU2007141518/15A patent/RU2007141518A/en unknown
- 2006-03-31 BR BRPI0610634-0A patent/BRPI0610634A2/en not_active Application Discontinuation
- 2006-03-31 EP EP06723901A patent/EP1888075A1/en not_active Withdrawn
- 2006-03-31 AU AU2006233567A patent/AU2006233567A1/en not_active Abandoned
- 2006-03-31 CN CNA2006800207814A patent/CN101193638A/en active Pending
- 2006-03-31 KR KR1020077026260A patent/KR20080007252A/en not_active Application Discontinuation
- 2006-04-07 SV SV2006002477A patent/SV2008002477A/en not_active Application Discontinuation
- 2006-04-10 GT GT200600145A patent/GT200600145A/en unknown
- 2006-04-11 AR ARP060101410A patent/AR053575A1/en unknown
- 2006-04-11 PE PE2006000383A patent/PE20061338A1/en not_active Application Discontinuation
- 2006-04-12 TW TW095112920A patent/TW200716122A/en unknown
- 2006-04-12 UY UY29473A patent/UY29473A1/en not_active Application Discontinuation
-
2007
- 2007-10-09 CR CR9427A patent/CR9427A/en not_active Application Discontinuation
- 2007-10-11 TN TNP2007000385A patent/TNSN07385A1/en unknown
- 2007-10-11 IL IL186604A patent/IL186604A0/en unknown
- 2007-10-29 MA MA30335A patent/MA29683B1/en unknown
Also Published As
Publication number | Publication date |
---|---|
CR9427A (en) | 2007-12-17 |
JP2008535877A (en) | 2008-09-04 |
AU2006233567A1 (en) | 2006-10-19 |
CN101193638A (en) | 2008-06-04 |
CA2605224A1 (en) | 2006-10-19 |
AR053575A1 (en) | 2007-05-09 |
WO2006108519A1 (en) | 2006-10-19 |
GT200600145A (en) | 2007-04-10 |
IL186604A0 (en) | 2008-01-20 |
MX2007012567A (en) | 2007-12-10 |
DE102005016981A1 (en) | 2006-10-19 |
BRPI0610634A2 (en) | 2010-07-13 |
EP1888075A1 (en) | 2008-02-20 |
SV2008002477A (en) | 2008-02-08 |
TNSN07385A1 (en) | 2009-03-17 |
TW200716122A (en) | 2007-05-01 |
PE20061338A1 (en) | 2007-01-28 |
KR20080007252A (en) | 2008-01-17 |
UY29473A1 (en) | 2006-11-30 |
RU2007141518A (en) | 2009-05-20 |
DOP2006000074A (en) | 2006-10-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MA29683B1 (en) | COMBINATION FOR TREATING A BENIGN HYPERPLASIE OF THE PROSTATE | |
MA31150B1 (en) | VEGF-SPECIFIC ANTAGONISTS FOR ADJUVANT AND NEOADJUVANT THERAPY AND TREATMENT OF FIRST-STAGE TUMORS | |
ATE509019T1 (en) | BENZODIAZEPINE PIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS | |
ATE394400T1 (en) | BICYCLIC ANILIDE SPIROHYDANTOINS AS CGRP RECEPTOR ANTAGONISTS | |
FR16C0021I2 (en) | AZETIDINES AS MEK INHIBITORS AND THEIR USE FOR THE TREATMENT OF PROLIFERATIVE DISEASES | |
MA30333B1 (en) | AMINOTETRAHYDROPYRANES USEFUL AS INHIBITORS OF DIPEPTIDYL PEPTIDASE-IV FOR THE TREATMENT OR PREVENTION OF DIABETES. | |
NO20054411L (en) | Therapeutic agents comprising an anti-angiogenic agent in combination with an SRC inhibitor and their therapeutic use | |
TR200302309T4 (en) | Beta-carboline derivatives as useful inhibitors of phosphodiesterase. | |
NO20072322L (en) | Lactam compounds and their use as pharmaceutical agents | |
TW200505903A (en) | CGRP receptor antagonists | |
DE60332433D1 (en) | AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR | |
DE60332604D1 (en) | AZOLYLAMINOAZINE AS PROTEIN KINASE INHIBITOR | |
MA32684B1 (en) | Picolinamide derivatives act as kinase inhibitors | |
ATE535514T1 (en) | CARBOXAMIDE SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS | |
MA27556A1 (en) | PHENYLALANINE DERIVATIVES AS DIPEPTIDYL PEPTIDASE INHIBITORS FOR THE TREATMENT OR PREVENTION OF DIABETES | |
NO20082880L (en) | Inhibitors of C-MET and its use | |
ATE464305T1 (en) | BICYCLIC ANILIDE SPIROLACTAMES AS ANTAGONISTS OF THE CGRP RECEPTOR | |
HRP20050529A2 (en) | Phenyl or heteroaryl amino alkane derivatives as ip receptor antagonist | |
MA29915B1 (en) | SUBSTITUTED BENZIMIDAZOLES AS KINASE INHIBITORS | |
DE60314603D1 (en) | COMPOSITIONS NECESSARY AS PROTEIN KINASE INHIBITORS | |
EA200700251A1 (en) | AMIDOCONOMINATION AND THEIR APPLICATION AS PHARMACEUTICAL FACILITIES | |
MX2007002311A (en) | Endothelin a receptor (eta) antagonists in combination with phosphodiesterase 5 inhibitors (pde5) and uses thereof. | |
DE602005024004D1 (en) | AS BETA SEKRETASE (BACE) HEMMER USEFUL 2-AMINO-CHINAZOLINE DERIVATIVES | |
EP1606264A4 (en) | Monocyclic anilide spirohydantoin cgrp receptor antagonists | |
ATE516803T1 (en) | ARYL SPIROHYDANTOIN CGRP RECEPTOR ANTAGONISTS |